The Michigan Institute for Clinical & Health Research (MICHR) at the University of Michigan has selected the OpenClinica Enterprise clinical trial software platform to support a growing clinical study portfolio. Starting this fall, MICHR will begin deployment of OpenClinica for a wide variety of clinical trials.
According to Jim Maszatics, Clinical Research Informatics Core (CRIC) Manager at MICHR, OpenClinica offers a robust infrastructure that will enhance MICHR’s competitiveness for extramural funding. “Static budgets and budget cuts from the NIH are causing government-sponsored grants to become more competitive than ever. With OpenClinica, we are able to put in place an enterprise-quality, regulatory compliant electronic data capture and clinical data management system that will make us more attractive to both government-sponsored and industry-sponsored clinical trials.”
In addition to its regulatory compliance capabilities, MICHR cited OpenClinica’s flexibility to support a wide variety of studies off the same platform, thereby increasing the institute’s efficiency. This efficiency will serve MICHR well in its support of a large and growing number of diverse clinical studies.
Zenocutuzumab Shows Durable Efficacy in NRG1 Fusion-Positive Cancers in Phase II eNRGy Trial
February 13th 2025The Phase II eNRGy trial showed durable antitumor activity with zenocutuzumab (Bizengri) in patients with NRG1 fusion–positive cancers, particularly non-small cell lung cancer and pancreatic cancer.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
Reaching Diverse Patient Populations With Personalized Treatment Methods
January 20th 2025Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical research including industry’s greatest challenges in reaching diverse patient populations, personalized treatment methods, recruitment strategies, and more.
SCOPE Summit 2025: Enhancing the Patient Experience Through Site Centricity
February 12th 2025In an interview with ACT senior editor Andy Studna at SCOPE Summit, Ashley Davidson, vice president, product lead - sponsor tech strategy, Advarra, highlights the need for more site-centric approaches in study startup.